breast cancer
Conditions
Interventions
Group N:Equal volume 0.9% sodium chloride infusion 10 minutes before anesthesia induction +intraoperative 0.9% sodium chloride infusion
Group L:1.5mg/kg lidocaine infusion 10 minutes before anesthesia induction + 0.9% intraoperative sodium chloride infusion
Group K:0.25mg/kg esketamine infusion 10 minutes before anesthesia induction + 0.9% sodium chloride infusion during the operation
Group LK:Infusion of 1.5mg/kg lidocaine and 0.25mg/kg esketamine 10 minutes before anesthesia induction + intraoperative infusion of 1.5mg/kg lidocaine and 0.06mg/kg esketamine
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? Female, age 20-65 years old; ?ASA grade I ~ ?; ? Patients with clinical stage 0, stage ?, stage ? and stage ? who underwent unilateral breast cancer surgery; (4) The surgical procedures are radical mastectomy with breast preservation, modified radical mastectomy, radical mastectomy or total mastectomy.
Exclusion criteria
Exclusion criteria: a. Preoperative concomitant mental and psychological disorders (such as depression and generalized anxiety disorder); b. Patients with a BMI = 30kg/m2; c. Those with a weight less than 40kg; d. Pregnant or lactating women; e. Individuals with severe heart, kidney, or liver diseases; f. Bilateral breast cancer surgery or previous breast cancer surgery history; g. Preoperative complications with chronic pain lasting more than 3 months or long-term regular use of painkillers; h. Individuals who are allergic or contraindicated to any medication in the experiment; i. Previous history of radiotherapy and chemotherapy; j. Participants in other relevant clinical trials and those who refuse to participate in the trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chronic pain 3 months after surgery (NRS score =1 will be considered positive); | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative use of remifentanil;Ramsay Sedation score ;resting VAS score after operation ;VAS score in activity state after operation;QOR-15 score after operation;incidence of neuropathic pain;incidence of moderate to severe postoperative chronic pain;the number and dosage of relief analgesia;SF-MPQ score after operation ;incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactYan Ming
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed